Details of the Drug Reposition

General Information of This Drug (ID: DM8X2EH)

• Drug Name: Everolimus (DM8X2EH)
• Synonyms: Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress
• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

15 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Salivary gland squamous cell carcinoma	DISDI0CT	N.A.	Approved	[1]
Mucosal melanoma	DISBZ12R	N.A.	Approved	[1]
Leukemia	DISNAKFL	N.A.	Approved	[1]
Intracranial meningioma	DISD09EF	N.A.	Approved	[1]
Breast carcinoma	DIS2UE88	N.A.	Approved	[1]
Brainstem neoplasm	DIS5NVUG	N.A.	Approved	[1]
Advanced cancer	DISAT1Z9	2A00-2F9Z	Approved	[1]
Plasma cell myeloma	DIS0DFZ0	2A83.1	Approved	[1]
Lung cancer	DISCM4YA	2C25.0	Approved	[1]
Prostate cancer	DISF190Y	2C82.0	Approved	[1]
Renal cell carcinoma	DISQZ2X8	2C90	Approved	[2]
Graft-versus-host disease	DIS0QADF	4B24	Approved	[1]
Multiple sclerosis	DISB2WZI	8A40	Approved	[1]
Tuberous sclerosis	DISEMUGZ	LD2D.2	Approved	[1]
Advanced/metastatic breast cancer	DISJUSVZ	2C60	Approved	[3]

1 Withdrawn Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Pemphigus	DISZAZ6M	N.A.	Withdrawn	[4]

3 Discontinued in Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Kidney angiomyolipoma	DISRCMMM	N.A.	Discontinued in Phase 3	[5]
Eosinophilic esophagitis	DISR8WSB	DA24.1	Discontinued in Phase 3	[6]
Rheumatoid arthritis	DISTSB4J	FA20	Discontinued in Phase 3	[7]

3 Discontinued in Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Eosinophilic gastroenteritis	DISYIW4H	N.A.	Discontinued in Phase 2	[8]
Squamous cell carcinoma	DISQVIFL	2B60-2D01	Discontinued in Phase 2	[9]
Metastatic melanoma	DISSL43L	2E2Z	Discontinued in Phase 2	[10]

7 Investigative Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Pancreatic acinar cell carcinoma	DISY1IQQ	N.A.	Investigative	[1]
Castration-resistant prostate carcinoma	DISVGAE6	N.A.	Investigative	[1]
Colon cancer	DISVC52G	2B90.Z	Investigative	[1]
Neuroblastoma	DISVZBI4	2D11.2	Investigative	[1]
Polycystic kidney disease	DISWS3UY	GB8Y	Investigative	[1]
Middle East Respiratory Syndrome (MERS)	DIS5VPYU	1D64	Investigative	[11]
Severe acute respiratory syndrome (SARS)	DISYW14W	1D65	Investigative	[11]

References

• [1] Everolimus FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5889).
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Novel Treatment for Syndromic Ichthyoses
• [5] Vytorin Treating Uncontrolled Lipids (VyTUL) Study (0653A-122)
• [6] ClinicalTrials.gov (NCT01534351) Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)
• [7] Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
• [8] ClinicalTrials.gov (NCT01652014) Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies
• [9] Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
• [10] Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression
• [11] Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.